Терапевтический архив (May 2016)

N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs

  • I G Kirillova,
  • D S Novikova,
  • T V Popkova,
  • E N Aleksandrova,
  • A A Novikov,
  • Yu N Gorbunova,
  • E I Markelova,
  • Yu O Korsakova,
  • S I Glukhova,
  • A V Volkov,
  • E L Luchikhina,
  • N V Demidova,
  • K A Kasumova,
  • S A Vladimirov,
  • M A Kanonirova,
  • G L Lukina,
  • D E Karateev,
  • E L Nasonov

Journal volume & issue
Vol. 88, no. 5
pp. 19 – 26

Abstract

Read online

Aim. To determine N-terminal pro-brain natriuretic peptide (NT-proBNP) levels in patients with early rheumatoid arthritis (RA) before the use of disease-modifying antirheumatic drugs (DMARDs); to compare NT-proBNP values with traditional risk factors (TRF), cardiovascular diseases (CVD), inflammatory markers, and left ventricular (LV) diastolic dysfunction (DD). Subjects and methods. The investigation enrolled 74 patients with a valid RA diagnosis (the 2010 ACR/EULAR criteria), 56 (74%) women, median (Me) age, 54 years; disease duration, 7 months; seropositive for IgM rheumatoid factor (87%) and/or anti-cyclic citrullinated peptide antibodies (100%) with no history of the use of DMARDs and glucocorticosteroids. Duplex scanning and echographic findings were used to assess TRF for CVD and carotid artery atherosclerosis (CAA) in all the patients with early RA prior to therapy. An E/A ratio was used as a criterion for LVDD. Results. NT-proBNP concentrations in patients with early RA proved to be higher than those in the control group (p

Keywords